Singapore markets close in 7 hours 47 minutes

Adamis Pharmaceuticals Corporation (ADMP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1985-0.0266 (-11.82%)
At close: 04:00PM EDT
0.2051 +0.01 (+3.32%)
After hours: 07:30PM EDT

Adamis Pharmaceuticals Corporation

11682 El Camino Real
Suite 300
San Diego, CA 92130
United States
858 997 2400

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees15

Key executives

NameTitlePayExercisedYear born
Mr. David J. MarguglioCo-Founder, CEO, Pres & Director490.68kN/A1970
Dr. Ronald B. Moss M.D.Chief Medical Officer693.2kN/A1961
Mr. David C. BenedictoChief Financial OfficerN/AN/A1961
Ms. Karen K. DanielsVP of OperationsN/AN/A1953
Mr. Mark FlatherSr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Jennifer C. SuskiSr. Director of MarketingN/AN/AN/A
Mr. Eddie Wabern GloverChief Exec. Officer of US Compounding IncN/AN/A1950
Mr. Robert B. RothermelConsultantN/AN/A1944
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.

Corporate governance

Adamis Pharmaceuticals Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.